⌘K
t
On April 28, 2026, Avacta Group PLC submitted a Block Listing Six Monthly Return covering the period from October 28, 2025, to April 27, 2026. Under the EMI scheme, 56,116 securities were allotted, leaving 68,442 unallotted securities. For the LTIP/ESOS scheme, 874,500 securities were allotted, with 309,162 securities remaining unallotted.
| Date | 28 Apr 2026 |
| Time | 07:00:11 |
| Category | Miscellaneous |
| ID | 0751C |
Block Listing Six Monthly Return
LONDON and PHILADELPHIA - April 28, 2026 Avacta Therapeutics (AIM: AVCT, 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Avacta Group plc |
|||
|
Name of scheme: |
EMI scheme |
|||
|
Period of return: |
From: |
28 October 2025 |
|
27 April 2026 |
|
Balance of unallotted securities under scheme(s) from previous return: |
124,558 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
56,116 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
68,442 |
|||
|
|
|
|
|
|
|
Name of applicant: |
Avacta Group plc |
||||
|
Name of scheme: |
LTIP/ESOS scheme |
||||
|
Period of return: |
From: |
28 October 2025 |
|
27 April 2026 |
|
|
Balance of unallotted securities under scheme(s): |
1,183,662 |
||||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
874,500 |
||||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
309,162 |
||||
|
|
|
|
|
|
|
|
|
|
||||
|
Name of contact: |
Brian Hahn, Company Secretary |
||||
|
Telephone number of contact: |
+ 44 (0) 1904 217070 |
||||
Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Christina Coughlin, Chief Executive Officer |
via Cohesion Bureau |
|
|
|
|
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance
|
|
|
Zeus (Broker) James Hornigold / George Duxberry / Dominic King
|
|
|
Cohesion Bureau Communications / Media / Investors Richard Jarvis
|
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.
Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma.
About FAP-Exd (AVA6103)
AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Gen Two innovative pre|CISION® sustained release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.